The FDA has approved specific formulations for different indications: semaglutide 2.4 mg (Wegovy), liraglutide 3 mg (Saxenda), and tirzepatide (Zepbound) are approved for chronic weight management, while all are approved for diabetes at different doses
JCI Insight 4 , e126742 (2019)
Delbecq AL, Van de Ven AH, Gustafson DH
10.1146/annurev-cellbio-101512-122326 Annu
Registered dietitian and protein bar aficionado Kelli McGrane tried 30 of the most popular brands on the market
The Precision Peptide Genetic Test maps 14 metabolic pathways and 49 peptide-related genetic variants, revealing predispositions in fat regulation (FTO rs9939609), glucose sensing (GIPR rs1800437), and appetite control that inform personalized treatment adjustments